Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

RGNXREGENXBIO Inc.

Nasdaq · CIK 0001590877
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts344

Identity from submissions API

NameREGENXBIO Inc.
CIK0001590877
TickersRGNX
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN471851754
LEI—
Fiscal year end1231
State of incorporation—
Phone240-552-8181
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • ReGenX Biosciences, LLC (2013-11-07T05:00:00.000Z → 2013-11-07T05:00:00.000Z)
Business address
9804 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
MD
Mailing address
9804 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
MD

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

806 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-10 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000715 005-89108 261538331 34 8224
2026-11-05 10-Q 10-Q 0001193125-26-448581 001-37553 261524782 34 15334792 1 1
2026-11-05 8-K 8-K 2.02,9.01 0001193125-26-448559 001-37553 261524739 34 529054 1 1
2026-11-03 4 PRIMARY DOCUMENT 0002062007-26-000007 5361
2026-11-03 4 PRIMARY DOCUMENT 0001521123-26-000010 5365
2026-11-03 4 PRIMARY DOCUMENT 0001700659-26-000018 5356
2026-11-03 4 PRIMARY DOCUMENT 0001789335-26-000010 5379
2026-10-16 8-K 8-K 5.02 0001193125-26-423376 001-37553 261464319 34 147797 1 1
2026-10-13 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000019617-26-000350 005-89108 261456261 34 6791
2026-09-23 8-K 8-K 1.01 0001193125-26-399377 001-37553 261401069 34 149897 1 1
2026-09-03 4 PRIMARY DOCUMENT 0002062007-26-000005 5364
2026-09-03 4 PRIMARY DOCUMENT 0001789335-26-000008 5385
2026-08-27 4 PRIMARY DOCUMENT 0002023732-26-000008 11813
2026-08-27 3 PRIMARY DOCUMENT 0002023732-26-000007 6825
2026-08-25 8-K 8-K 5.02,9.01 0001193125-26-365287 001-37553 261316620 34 203373 1 1
2026-08-24 8-K 8-K 7.01,8.01,9.01 0001193125-26-363786 001-37553 261311621 34 206280 1 1
2026-08-06 10-Q 10-Q 0001193125-26-336725 001-37553 261245962 34 15527783 1 1
2026-08-06 8-K 8-K 2.02,9.01 0001193125-26-336716 001-37553 261245945 34 574068 1 1
2026-08-04 4 PRIMARY DOCUMENT 0001700659-26-000016 8696
2026-08-04 4 PRIMARY DOCUMENT 0001521123-26-000008 5364
2026-07-20 8-K 8-K 8.01,9.01 0001193125-26-308342 001-37553 261185172 34 495424 1 1
2026-07-17 424B5 424B5 0001193125-26-308027 333-291816 261184665 33 678385
2026-07-17 FWP FWP 0001193125-26-306576 333-291816 261181745 34 80744
2026-07-16 424B5 424B5 0001193125-26-306170 333-291816 261180726 33 649811
2026-07-06 4 PRIMARY DOCUMENT 0001346164-26-000006 9461
2026-07-06 4 PRIMARY DOCUMENT 0001700659-26-000014 9182
2026-07-06 SC TO-I/A SC TO-I/A 0001193125-26-295587 005-89108 261154310 34 39921
2026-07-01 4 PRIMARY DOCUMENT 0001700659-26-000012 11214
2026-07-01 144 xsl144X01/primary_doc.xml 0001950047-26-006719 001-37553 261145708 33 6565
2026-07-01 SC TO-I/A SC TO-I/A 0001193125-26-291681 005-89108 261142930 34 98645
2026-06-29 8-K 8-K 8.01,9.01 0001193125-26-286825 001-37553 261131300 34 213785 1 1
2026-06-04 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000019617-26-000236 005-89108 261064039 34 7213
2026-06-03 SC TO-I SC TO-I 0001193125-26-254638 005-89108 261058977 34 11982156
2026-06-03 8-K 8-K 5.07,8.01 0001193125-26-254590 001-37553 261058928 34 172660 1 1
2026-06-02 4 PRIMARY DOCUMENT 0001502785-26-000001 7591
2026-06-02 4 PRIMARY DOCUMENT 0001191235-26-000003 7468
2026-06-02 4 PRIMARY DOCUMENT 0001737231-26-000002 7601
2026-06-02 4 PRIMARY DOCUMENT 0001652824-26-000003 7609
2026-06-02 4 PRIMARY DOCUMENT 0001134365-26-000001 7605
2026-06-02 4 PRIMARY DOCUMENT 0001191229-26-000002 7520
2026-06-02 4 PRIMARY DOCUMENT 0001658390-26-000001 7619
2026-06-02 4 PRIMARY DOCUMENT 0001652936-26-000001 10941
2026-06-02 4 PRIMARY DOCUMENT 0001872219-26-000001 7603
2026-05-14 10-Q 10-Q 0001193125-26-222804 001-37553 26975853 34 12763951 1 1
2026-05-14 8-K 8-K 2.02,7.01,8.01,9.01 0001193125-26-222768 001-37553 26975816 34 976710 1 1
2026-05-13 4 PRIMARY DOCUMENT 0001700659-26-000010 5601
2026-05-12 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000286 005-89108 26966967 34 8252
2026-05-11 144 xsl144X01/primary_doc.xml 0001950047-26-004334 001-37553 26963840 33 5763
2026-04-14 ARS ARS 0001193125-26-155100 001-37553 26861645 34 2562649
2026-04-14 DEFA14A DEFA14A 0001193125-26-155070 001-37553 26861534 34 1260172
2026-04-14 DEF 14A DEF 14A 0001193125-26-155058 001-37553 26861499 34 4603334 1 1
2026-04-03 PRE 14A PRE 14A 0001193125-26-142245 001-37553 26838513 34 4603596 1 1
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-002154 005-89108 26803188 34 7250
2026-03-20 8-K 8-K 1.01 0001193125-26-117913 001-37553 26779157 34 147706 1 1
2026-03-12 4 PRIMARY DOCUMENT 0001700659-26-000008 5002
2026-03-10 144 xsl144X01/primary_doc.xml 0001950047-26-002438 001-37553 26739883 33 4888
2026-03-05 10-K 10-K 0001193125-26-094013 001-37553 26726432 34 20476288 1 1
2026-03-05 8-K 8-K 2.02,9.01 0001193125-26-092566 001-37553 26724197 34 552271 1 1
2026-02-12 424B5 424B5 0001193125-26-048688 333-291816 26626115 33 576175
2026-02-10 8-K 8-K 7.01,8.01,9.01 0001193125-26-043342 001-37553 26613269 34 208153 1 1
2026-02-03 4 PRIMARY DOCUMENT 0001521123-26-000006 5229
2026-02-03 4 PRIMARY DOCUMENT 0001700659-26-000006 5220
2026-01-29 4 PRIMARY DOCUMENT 0001652824-26-000002 9330
2026-01-28 8-K 8-K 8.01,9.01 0001193125-26-026139 001-37553 26568544 34 205215 1 1
2026-01-21 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-26-000190 005-89108 26545741 34 10984
2026-01-08 4 PRIMARY DOCUMENT 0001700659-26-000004 7672
2026-01-08 4 PRIMARY DOCUMENT 0002062007-26-000003 7676
2026-01-08 4 PRIMARY DOCUMENT 0001346164-26-000004 7681
2026-01-08 4 PRIMARY DOCUMENT 0001521123-26-000004 7681
2026-01-08 4 PRIMARY DOCUMENT 0001789335-26-000002 7695
2026-01-06 4 PRIMARY DOCUMENT 0001346164-26-000002 5301
2026-01-06 4 PRIMARY DOCUMENT 0002062007-26-000002 5283
2026-01-06 4 PRIMARY DOCUMENT 0001521123-26-000002 5287
2026-01-06 4 PRIMARY DOCUMENT 0001700659-26-000003 5296
2025-12-12 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-003711 333-291816 251569882 33 1884
2025-12-09 CORRESP filename1.htm 0001193125-25-312817 6638
2025-11-26 S-3 S-3 0001193125-25-300539 333-291816 251530456 33 622357 1 1
2025-11-06 8-K 8-K 2.02,9.01 0001193125-25-268101 001-37553 251456198 34 533431 1 1
2025-11-06 10-Q 10-Q 0001193125-25-268095 001-37553 251456164 34 13834678 1 1
2025-10-10 4 PRIMARY DOCUMENT 0001346164-25-000005 5470
2025-10-09 144 xsl144X01/primary_doc.xml 0001950047-25-007868 001-37553 251385290 33 6400
2025-10-01 4 PRIMARY DOCUMENT 0001346164-25-000003 5469
2025-09-12 4 PRIMARY DOCUMENT 0001562180-25-006194 5469
2025-09-10 144 xsl144X01/primary_doc.xml 0001950047-25-006948 001-37553 251306311 33 5127
2025-09-03 4 PRIMARY DOCUMENT 0001562180-25-006079 5225
2025-09-03 4 PRIMARY DOCUMENT 0001562180-25-006078 5245
2025-08-18 8-K 8-K 8.01,9.01 0000950170-25-109829 001-37553 251228787 34 207120 1 1
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-078638 005-89108 251219516 34 18881
2025-08-07 10-Q 10-Q 0001193125-25-174953 001-37553 251191608 34 15205900 1 1
2025-08-07 8-K 8-K 1.01,2.02,7.01,9.01 0001193125-25-174947 001-37553 251191573 34 616419 1 1
2025-08-04 4 PRIMARY DOCUMENT 0001562180-25-005618 5227
2025-07-15 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-002222 005-89108 251125553 34 10933
2025-07-03 4 PRIMARY DOCUMENT 0001562180-25-005334 5219
2025-06-25 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002024 333-288053 251074971 33 1884
2025-06-25 424B3 424B3 0001193125-25-146911 333-288053 251073793 33 254019
2025-06-23 CORRESP filename1.htm 0001193125-25-144857 7186
2025-06-20 UPLOAD filename1.pdf 0000000000-25-006467 333-288053 40153
2025-06-13 S-3 S-3 0001193125-25-140870 333-288053 251047726 33 429558
2025-06-13 S-8 S-8 0000950170-25-086259 333-288040 251047105 33 450554
2025-06-03 4 PRIMARY DOCUMENT 0001562180-25-004355 10802
2025-06-03 4 PRIMARY DOCUMENT 0001562180-25-004354 7461
2025-06-03 4 PRIMARY DOCUMENT 0001562180-25-004353 7451
2025-06-03 4 PRIMARY DOCUMENT 0001562180-25-004352 7328
2025-06-03 4 PRIMARY DOCUMENT 0001562180-25-004351 7472
2025-06-03 4 PRIMARY DOCUMENT 0001562180-25-004350 7465
2025-06-03 4 PRIMARY DOCUMENT 0001562180-25-004349 7479
2025-06-03 4 PRIMARY DOCUMENT 0001562180-25-004348 7340
2025-06-03 4 PRIMARY DOCUMENT 0001562180-25-004347 7463
2025-06-03 8-K 8-K 5.07 0000950170-25-080986 001-37553 251020082 34 173169 1 1
2025-05-19 8-K 8-K 1.01,2.03,7.01,9.01 0001193125-25-122456 001-37553 25964087 34 175432 1 1
2025-05-14 4 PRIMARY DOCUMENT 0001562180-25-003822 9467
2025-05-12 144 xsl144X01/primary_doc.xml 0001950047-25-002911 001-37553 25935294 33 4894
2025-05-12 10-Q 10-Q 0000950170-25-069237 001-37553 25935049 34 12781680 1 1
2025-05-12 8-K 8-K 2.02,9.01 0000950170-25-069211 001-37553 25934927 34 472839 1 1
2025-04-24 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-001546 005-89108 25863857 34 10935
2025-04-14 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-001101 333-269086 25837450 33 1896
2025-04-08 ARS ARS 0000950170-25-052088 001-37553 25822293 34 1809928
2025-04-08 DEFA14A DEFA14A 0000950170-25-052082 001-37553 25822222 34 1266104
2025-04-08 DEF 14A DEF 14A 0000950170-25-052069 001-37553 25822120 34 11528802 1 1
2025-04-04 4 PRIMARY DOCUMENT 0001562180-25-003010 5213
2025-04-04 4 PRIMARY DOCUMENT 0001562180-25-003009 5218
2025-04-04 4 PRIMARY DOCUMENT 0001562180-25-003008 5223
2025-03-31 4 PRIMARY DOCUMENT 0001562180-25-002804 7337
2025-03-24 3 PRIMARY DOCUMENT 0001562180-25-002709 14655
2025-03-13 S-8 S-8 0000950170-25-038862 333-285797 25736682 33 163072
2025-03-13 POS AM POS AM 0001193125-25-053998 333-269086 25736561 33 2005163
2025-03-13 10-K 10-K 0000950170-25-038770 001-37553 25736077 34 22871093 1 1
2025-03-13 POSASR POSASR 0001193125-25-053917 333-269086 25735881 33 2074570
2025-03-13 8-K 8-K 2.02,9.01 0000950170-25-038711 001-37553 25735701 34 519630 1 1
2025-03-04 8-K 8-K 7.01,8.01,9.01 0001193125-25-045585 001-37553 25704264 34 164462 1 1
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000019617-25-000259 005-89108 25614385 34 6860
2025-02-05 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000093751-25-000088 005-89108 25590931 34 8077
2025-01-31 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000211 005-89108 25576314 34 6372
2025-01-14 4/A PRIMARY DOCUMENT 0001562180-25-000360 6153
2025-01-14 8-K 8-K 1.01,7.01,9.01 0001193125-25-005659 001-37553 25527747 34 178990 1 1
2025-01-08 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-000047 005-89108 25519635 34 44857
2025-01-06 4 PRIMARY DOCUMENT 0001562180-25-000190 9608
2025-01-06 4 PRIMARY DOCUMENT 0001562180-25-000189 9610
2025-01-06 4 PRIMARY DOCUMENT 0001562180-25-000188 9613
2025-01-06 4 PRIMARY DOCUMENT 0001562180-25-000187 9180
2025-01-06 4 PRIMARY DOCUMENT 0001562180-25-000186 7748
2024-12-30 144 xsl144X01/primary_doc.xml 0001950047-24-010094 001-37553 241589838 33 4910
2024-12-09 424B5 424B5 0001193125-24-273517 333-269086 241535974 33 527182 1 1
2024-12-09 8-K 8-K 8.01,9.01 0001193125-24-273467 001-37553 241535656 34 497806 1 1
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-119431 005-89108 241465542 34 107916
2024-11-12 SC 13G/A UnitedStates_13G__REGENXBIOI.txt 0000932471-24-001135 005-89108 241449319 34 6675
2024-11-06 10-Q 10-Q 0000950170-24-122330 001-37553 241431157 34 10333170 1 1
2024-11-06 8-K 8-K 2.02,9.01 0000950170-24-122300 001-37553 241431007 34 435962 1 1
2024-11-04 SC 13G/A UnitedStates_13G__REGENXBIOI.txt 0000932471-24-000670 005-89108 241422382 34 5752
2024-10-17 SC 13G/A FILING REGENXBIO INC. 0000019617-24-000592 005-89108 34 90052
2024-10-02 4 PRIMARY DOCUMENT 0001562180-24-007144 9288
2024-09-18 4 PRIMARY DOCUMENT 0001562180-24-006869 8045
2024-09-18 3 PRIMARY DOCUMENT 0001562180-24-006868 6742
2024-09-17 8-K 8-K 5.02,7.01,9.01 0000950170-24-107367 001-37553 241305169 34 213975 1 1
2024-09-04 4 PRIMARY DOCUMENT 0001562180-24-006657 11277
2024-08-12 4 PRIMARY DOCUMENT 0001562180-24-006146 7990
2024-08-06 8-K 8-K 5.02 0001193125-24-194111 001-37553 241176436 34 140491 1 1
2024-08-05 4 PRIMARY DOCUMENT 0001562180-24-006017 5230
2024-08-05 4 PRIMARY DOCUMENT 0001562180-24-006016 5224
2024-08-05 4 PRIMARY DOCUMENT 0001562180-24-006015 16699
2024-08-05 4 PRIMARY DOCUMENT 0001562180-24-006014 5043
2024-08-05 4 PRIMARY DOCUMENT 0001562180-24-006013 7316
2024-08-01 144 xsl144X01/primary_doc.xml 0001950047-24-005776 001-37553 241167326 33 6458
2024-08-01 10-Q 10-Q 0000950170-24-089320 001-37553 241167037 34 10266033 1 1
2024-08-01 8-K 8-K 2.02,9.01 0000950170-24-089278 001-37553 241166709 34 437029 1 1
2024-07-30 4 PRIMARY DOCUMENT 0001562180-24-005875 9235
2024-07-30 4 PRIMARY DOCUMENT 0001562180-24-005874 5476
2024-07-29 144 xsl144X01/primary_doc.xml 0001950047-24-005640 001-37553 241152493 33 5134
2024-07-26 4 PRIMARY DOCUMENT 0001562180-24-005855 15142
2024-07-18 4 PRIMARY DOCUMENT 0001562180-24-005798 14705
2024-07-03 4 PRIMARY DOCUMENT 0001562180-24-005567 8017
2024-07-03 4 PRIMARY DOCUMENT 0001562180-24-005566 9309
2024-07-01 144 xsl144X01/primary_doc.xml 0001950047-24-005142 001-37553 241091289 33 5014
2024-06-13 8-K 8-K 5.02,7.01,9.01 0001193125-24-160146 001-37553 241039844 34 179119 1 1
2024-06-04 4 PRIMARY DOCUMENT 0001562180-24-004656 7447
2024-06-04 4 PRIMARY DOCUMENT 0001562180-24-004655 7473
2024-06-04 4 PRIMARY DOCUMENT 0001562180-24-004654 7348
2024-06-04 4 PRIMARY DOCUMENT 0001562180-24-004653 7487
2024-06-04 4 PRIMARY DOCUMENT 0001562180-24-004652 7471
2024-06-04 4 PRIMARY DOCUMENT 0001562180-24-004651 10810
2024-06-04 4 PRIMARY DOCUMENT 0001562180-24-004650 7459
2024-06-04 4 PRIMARY DOCUMENT 0001562180-24-004649 7336
2024-06-03 8-K 8-K 5.07,9.01 0000950170-24-068050 001-37553 241014200 34 162348 1 1
2024-05-16 4 PRIMARY DOCUMENT 0001562180-24-004104 9528
2024-05-14 144 xsl144X01/primary_doc.xml 0001950047-24-003648 001-37553 24944738 33 6643
2024-05-08 10-Q 10-Q 0000950170-24-055691 001-37553 24926318 34 9060599 1 1
2024-05-08 8-K 8-K 2.02,9.01 0000950170-24-055656 001-37553 24926111 34 392396 1 1
2024-04-17 4 PRIMARY DOCUMENT 0001562180-24-003452 9527
2024-04-04 ARS ARS 0000950170-24-041819 001-37553 24823364 34 1915602
2024-04-04 DEFA14A DEFA14A 0000950170-24-041814 001-37553 24823307 34 1209199
2024-04-04 DEF 14A DEF 14A 0000950170-24-041805 001-37553 24823253 34 5815586 1 1
2024-03-21 4 PRIMARY DOCUMENT 0001562180-24-002907 7328
2024-03-18 4 PRIMARY DOCUMENT 0001562180-24-002771 9528
2024-03-11 8-K 8-K 8.01,9.01 0001193125-24-064353 001-37553 24736578 34 527408 1 1
2024-03-08 424B5 424B5 0001193125-24-062813 333-269086 24732252 33 530974
2024-03-07 4 PRIMARY DOCUMENT 0001562180-24-002430 12434
2024-03-07 FWP FWP 0001193125-24-061273 333-269086 24728015 34 78697
2024-03-06 424B5 424B5 0001193125-24-060745 333-269086 24726225 33 489309
2024-03-05 144 xsl144X01/primary_doc.xml 0001950047-24-001869 001-37553 24720917 33 5622
2024-02-27 S-8 S-8 0000950170-24-021296 333-277412 24687949 33 129762
2024-02-27 10-K 10-K 0000950170-24-021161 001-37553 24686937 34 17870185 1 1
2024-02-27 8-K 8-K 2.02,9.01 0000950170-24-021130 001-37553 24686771 34 443273 1 1
2024-02-16 4 PRIMARY DOCUMENT 0001562180-24-001395 11488
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023775 005-89108 24638931 34 104918
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-021818 005-89108 24629460 34 13159
2024-02-05 SC 13G/A SC 13G/A 0001140361-24-005627 005-89108 24595380 34 57200
2024-01-25 SC 13G/A FILING REGENXBIO INC. 0000019617-24-000155 005-89108 34 90067
2024-01-25 SC 13G/A FILING REGENXBIO INC. 0000019617-24-000144 005-89108 34 90067
2024-01-25 SC 13G/A REGENXBIO_Inc.txt 0000093751-24-000190 005-89108 24558568 34 8631
2024-01-19 SC 13G/A us75901b1070_011924.txt 0001086364-24-000398 005-89108 24545224 34 13603
2024-01-18 4 PRIMARY DOCUMENT 0001562180-24-000544 9496
2024-01-16 144 xsl144X01/primary_doc.xml 0001950047-24-000307 001-37553 24535445 33 5703
2024-01-04 4 PRIMARY DOCUMENT 0001562180-24-000257 9602
2024-01-04 4 PRIMARY DOCUMENT 0001562180-24-000252 11687
2024-01-04 4 PRIMARY DOCUMENT 0001562180-24-000249 13697
2024-01-04 4 PRIMARY DOCUMENT 0001562180-24-000246 9595
2024-01-04 4 PRIMARY DOCUMENT 0001562180-24-000223 9596
2024-01-04 4 PRIMARY DOCUMENT 0001562180-24-000219 9582
2024-01-03 144 xsl144X01/primary_doc.xml 0001950047-24-000131 001-37553 24506786 33 4897
2023-12-21 4 PRIMARY DOCUMENT 0001562180-23-008519 13511
2023-12-19 144 xsl144X01/primary_doc.xml 0001950047-23-006320 001-37553 231497727 33 4979
2023-11-17 SC 13G SC 13G 0001104659-23-119604 005-89108 231419907 34 96916
2023-11-08 10-Q 10-Q 0000950170-23-061144 001-37553 231388091 34 11790222 1 1
2023-11-08 8-K 8-K 2.02,9.01 0000950170-23-061110 001-37553 231387915 34 533089 1 1
2023-09-01 424B5 424B5 0001193125-23-227707 333-269086 231233122 33 418653
2023-09-01 8-K 8-K 8.01,9.01 0001193125-23-227647 001-37553 231232650 34 401644 1 1
2023-08-04 S-3ASR S-3ASR 0001193125-23-203922 333-273727 231144485 33 250789
2023-08-02 10-Q 10-Q 0000950170-23-037178 001-37553 231135809 34 12603004 1 1
2023-08-02 8-K 8-K 2.02,9.01 0000950170-23-037162 001-37553 231135673 34 608293 1 1
2023-06-06 4 PRIMARY DOCUMENT 0001562180-23-004896 14043
2023-06-06 4 PRIMARY DOCUMENT 0001562180-23-004894 10697
2023-06-06 4 PRIMARY DOCUMENT 0001562180-23-004893 7253
2023-06-06 4 PRIMARY DOCUMENT 0001562180-23-004892 10754
2023-06-06 4 PRIMARY DOCUMENT 0001562180-23-004891 10774
2023-06-06 4 PRIMARY DOCUMENT 0001562180-23-004890 7265
2023-06-06 4 PRIMARY DOCUMENT 0001562180-23-004889 10728
2023-06-06 4 PRIMARY DOCUMENT 0001562180-23-004888 10716
2023-06-05 8-K 8-K 5.07,9.01 0000950170-23-026437 001-37553 23993798 34 189129 1 1
2023-06-02 4 PRIMARY DOCUMENT 0001562180-23-004722 11583
2023-05-10 SC 13G/A SCHEDULE 13G/A 0001104659-23-058100 005-89108 23904714 34 13070
2023-05-03 10-Q 10-Q 0000950170-23-017200 001-37553 23884212 34 10823281 1 1
2023-05-03 8-K 8-K 2.02,9.01 0000950170-23-017184 001-37553 23883842 34 551819 1 1
2023-04-07 SC 13G SC 13G 0001140361-23-017270 005-89108 23808244 34 56087
2023-04-06 ARS ARS 0000950170-23-012081 001-37553 23806465 34 1271818
2023-04-06 DEFA14A DEFA14A 0000950170-23-012078 001-37553 23806359 34 934050
2023-04-06 DEF 14A DEF 14A 0000950170-23-012070 001-37553 23806277 34 5774347 1 1
2023-02-28 S-8 S-8 0000950170-23-005157 333-270116 23686233 33 172074
2023-02-28 10-K 10-K 0000950170-23-005085 001-37553 23685384 34 21189065 1 1
2023-02-28 8-K 8-K 2.02,9.01 0000950170-23-005077 001-37553 23685254 34 665455 1 1
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-016830 005-89108 23604151 34 13077
2023-02-03 SC 13G/A REGENXBIO_Inc.txt 0000093751-23-000151 005-89108 23584867 34 8578
2023-01-27 SC 13G/A FILING REGENXBIO INC. 0000019617-23-000166 005-89108 34 89856
2023-01-23 SC 13G/A us75901b1070_012323.txt 0001306550-23-002197 005-89108 23544216 34 13346
2023-01-10 8-K 8-K 5.02,9.01 0001193125-23-005019 001-37553 23519604 34 166744 1 1
2023-01-05 4 PRIMARY DOCUMENT 0001562180-23-000224 9460
2023-01-05 4 PRIMARY DOCUMENT 0001562180-23-000223 9466
2023-01-05 4 PRIMARY DOCUMENT 0001562180-23-000222 11554
2023-01-05 4 PRIMARY DOCUMENT 0001562180-23-000220 9457
2023-01-05 4 PRIMARY DOCUMENT 0001562180-23-000221 9460
2023-01-05 4 PRIMARY DOCUMENT 0001562180-23-000219 9446
2022-12-30 S-3ASR S-3ASR 0001193125-22-315441 333-269086 221502168 33 424305
2022-11-03 10-Q 10-Q 0000950170-22-021567 001-37553 221356320 34 12818390 1 1
2022-11-03 8-K 8-K 2.02,9.01 0000950170-22-021548 001-37553 221356231 34 651306 1 1
2022-08-31 4 PRIMARY DOCUMENT 0001562180-22-006398 5362
2022-08-08 4 PRIMARY DOCUMENT 0001562180-22-005938 6890
2022-08-03 4 PRIMARY DOCUMENT 0001562180-22-005876 5362
2022-08-03 10-Q 10-Q 0001564590-22-027764 001-37553 221132707 34 11503587 1 1
2022-08-03 8-K 8-K 2.02,9.01 0001564590-22-027754 001-37553 221132545 34 579452 1 1
2022-07-15 4 PRIMARY DOCUMENT 0001562180-22-005681 6894
2022-06-07 4 PRIMARY DOCUMENT 0001562180-22-004883 7382
2022-06-07 3 PRIMARY DOCUMENT 0001562180-22-004882 6610
2022-06-07 4 PRIMARY DOCUMENT 0001562180-22-004881 7334
2022-06-07 4 PRIMARY DOCUMENT 0001562180-22-004880 7211
2022-06-07 4 PRIMARY DOCUMENT 0001562180-22-004879 7348
2022-06-07 4 PRIMARY DOCUMENT 0001562180-22-004878 7223
2022-06-07 4 PRIMARY DOCUMENT 0001562180-22-004876 7362
2022-06-07 4 PRIMARY DOCUMENT 0001562180-22-004875 7346
2022-06-07 4 PRIMARY DOCUMENT 0001562180-22-004873 7346
2022-06-07 8-K 8-K 5.02,5.07,9.01 0001193125-22-168821 001-37553 22999804 34 171417 1 1
2022-05-04 10-Q 10-Q 0001564590-22-017878 001-37553 22892068 34 10043798 1 1
2022-05-04 8-K 8-K 2.02,9.01 0001564590-22-017853 001-37553 22891631 34 506592 1 1
2022-04-07 DEFA14A DEFA14A 0001564590-22-013846 001-37553 22814021 34 1206815
2022-04-07 DEF 14A DEF 14A 0001564590-22-013843 001-37553 22813967 34 2040075
2022-03-25 8-K 8-K 1.01 0001193125-22-085244 001-37553 22772067 34 143251 1 1
2022-03-18 8-K 8-K 5.02 0001193125-22-079590 001-37553 22753254 34 139331 1 1
2022-03-01 S-8 S-8 0001564590-22-008117 333-263182 22699881 33 116483
2022-03-01 10-K 10-K 0001564590-22-008055 001-37553 22698502 34 18796787 1 1
2022-03-01 8-K 8-K 2.02,9.01 0001564590-22-008037 001-37553 22698106 34 641752 1 1
2022-02-14 SC 13G/A SCHEDULE 13G/A 0001104659-22-023155 005-89108 22634483 34 75604
2022-02-14 8-K 8-K 7.01,8.01,9.01 0001193125-22-039357 001-37553 22625134 34 178657 1 1
2022-02-11 SC 13G/A REGENXBIO_INC.txt 0000093751-22-000332 005-89108 22622864 34 8554
2022-02-11 SC 13G/A SC 13G/A 0001193125-22-034960 005-89108 22616351 34 38186
2022-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-22-018439 005-89108 22610678 34 13072
2022-02-09 8-K 8-K 7.01,8.01,9.01 0001193125-22-032205 001-37553 22605186 34 221607 1 1
2022-01-27 SC 13G/A us75901b1070_012722.txt 0000834237-22-002685 005-89108 22564271 34 13370
2022-01-26 SC 13G/A us75901b1070_012622.txt 0000834237-22-001268 005-89108 22556095 34 13370
2022-01-24 4 PRIMARY DOCUMENT 0001562180-22-000597 8242
2022-01-18 SC 13G/A FILING REGENXBIO INC. 0000019617-22-000112 005-89108 34 89991
2022-01-04 4 PRIMARY DOCUMENT 0001562180-22-000170 7565
2022-01-04 4 PRIMARY DOCUMENT 0001562180-22-000168 9062
2022-01-04 4 PRIMARY DOCUMENT 0001562180-22-000159 11140
2022-01-04 4 PRIMARY DOCUMENT 0001562180-22-000156 13159
2022-01-04 4 PRIMARY DOCUMENT 0001562180-22-000155 9041
2022-01-04 4 PRIMARY DOCUMENT 0001562180-22-000149 9056
2021-12-27 4 PRIMARY DOCUMENT 0001562180-21-007876 12205
2021-12-06 4 PRIMARY DOCUMENT 0001562180-21-007473 4949
2021-11-15 8-K 8-K 1.01 0001193125-21-328962 001-37553 211406396 34 141248 1 1
2021-11-12 8-K 8-K 7.01,8.01,9.01 0001193125-21-328180 001-37553 211404248 34 183886 1 1
2021-11-10 4 PRIMARY DOCUMENT 0001562180-21-006967 8922
2021-11-09 8-K 8-K 7.01,8.01,9.01 0001193125-21-324463 001-37553 211392292 34 165592 1 1
2021-11-09 SC 13G/A FILING REGENXBIO INC. 0000019617-21-000473 005-89108 34 90011
2021-11-02 10-Q 10-Q 0001564590-21-053565 001-37553 211371513 34 13020407 1 1
2021-11-02 8-K 8-K 2.02,9.01 0001564590-21-053557 001-37553 211371422 34 658874 1 1
2021-10-12 8-K 8-K 7.01,8.01,9.01 0001193125-21-296140 001-37553 211316642 34 179955 1 1
2021-10-01 8-K 8-K 7.01,8.01,9.01 0001193125-21-289652 001-37553 211298783 34 185577 1 1
2021-09-29 4 PRIMARY DOCUMENT 0001562180-21-006147 8922
2021-09-21 4 FORM 4 SUBMISSION 0000899243-21-036773 8566
2021-09-15 4 PRIMARY DOCUMENT 0001562180-21-005947 19335
2021-09-13 8-K 8-K 1.01,7.01,9.01 0001193125-21-270811 001-37553 211248556 34 208209 1 1
2021-09-08 4 PRIMARY DOCUMENT 0001562180-21-005879 5581
2021-09-08 4 PRIMARY DOCUMENT 0001562180-21-005878 5579
2021-09-08 3 PRIMARY DOCUMENT 0001562180-21-005877 6650
2021-09-08 3 PRIMARY DOCUMENT 0001562180-21-005876 6618
2021-09-07 8-K 8-K 5.02,9.01 0001193125-21-265999 001-37553 211238247 34 168080 1 1
2021-08-09 10-Q 10-Q 0001564590-21-042652 001-37553 211156722 34 10783593 1 1
2021-08-09 8-K 8-K 2.02,9.01 0001564590-21-042634 001-37553 211156590 34 600807 1 1
2021-07-29 4 PRIMARY DOCUMENT 0001562180-21-005088 8243
2021-07-16 8-K 8-K 8.01 0001193125-21-216928 001-37553 211094259 34 147228 1 1
2021-06-28 4 PRIMARY DOCUMENT 0001562180-21-004525 14624
2021-06-08 4 PRIMARY DOCUMENT 0001562180-21-004131 5481
2021-06-08 4 PRIMARY DOCUMENT 0001562180-21-004130 5358
2021-06-08 4 PRIMARY DOCUMENT 0001562180-21-004129 5370
2021-06-08 4 PRIMARY DOCUMENT 0001562180-21-004127 5509
2021-06-08 4 PRIMARY DOCUMENT 0001562180-21-004126 5493
2021-06-08 4 PRIMARY DOCUMENT 0001562180-21-004125 5477
2021-06-08 4 PRIMARY DOCUMENT 0001562180-21-004122 5494
2021-06-07 8-K 8-K 5.03,5.07,9.01 0001564590-21-031957 001-37553 21999734 34 230355 1 1
2021-05-05 10-Q 10-Q 0001564590-21-024116 001-37553 21893839 34 9348147 1 1
2021-05-05 8-K 8-K 2.02,9.01 0001564590-21-024099 001-37553 21893692 34 527958 1 1
2021-04-19 DEFA14A DEFA14A 0001564590-21-019424 001-37553 21834981 34 267716
2021-04-19 DEF 14A DEF 14A 0001564590-21-019415 001-37553 21834787 34 3052522
2021-04-08 PRE 14A PRE 14A 0001564590-21-018177 001-37553 21815099 34 3053557
2021-03-29 SEC STAFF LETTER filename1.pdf 9999999997-21-000994 274759
2021-03-01 4 PRIMARY DOCUMENT 0001562180-21-001682 9651
2021-03-01 S-8 S-8 0001564590-21-009914 333-253725 21698801 33 97713
2021-03-01 10-K 10-K 0001564590-21-009855 001-37553 21697831 34 20610520 1 1
2021-03-01 8-K 8-K 2.02,9.01 0001564590-21-009847 001-37553 21697723 34 642935 1 1
2021-03-01 SEC STAFF LETTER filename1.pdf 9999999997-21-000612 276491
2021-02-17 4 PRIMARY DOCUMENT 0001562180-21-001215 9418
2021-02-16 SC 13G/A SCHEDULE 13G/A 0001104659-21-023938 005-89108 21638273 34 71525
2021-02-16 SC 13G/A REGENXBIO_INC.txt 0000093751-21-000428 005-89108 21633013 34 8565
2021-02-12 SC 13G/A SC 13G/A 0001193125-21-041637 005-89108 21628049 34 38865
2021-02-12 SC 13G/A SC 13G/A 0001193125-21-041576 48108
2021-02-12 SC 13G/A SC 13G/A 0001193125-21-041544 005-89108 21627580 34 126917
2021-02-10 4 PRIMARY DOCUMENT 0001562180-21-001045 9419
2021-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-21-018971 005-89108 21611871 34 13975
2021-02-04 4 PRIMARY DOCUMENT 0001562180-21-000913 11410
2021-01-27 4 PRIMARY DOCUMENT 0001562180-21-000562 14088
2021-01-26 SC 13G/A us75901b1070_012621.txt 0000834237-21-001277 005-89108 21553191 34 13419
2021-01-20 4 PRIMARY DOCUMENT 0001562180-21-000379 5402
2021-01-15 SC 13G FILING REGENXBIO INC. 0000019617-21-000085 005-89108 34 89935
2021-01-14 4 PRIMARY DOCUMENT 0001562180-21-000345 18775
2021-01-14 4 PRIMARY DOCUMENT 0001562180-21-000344 6974
2021-01-12 4 PRIMARY DOCUMENT 0001562180-21-000307 28803
2021-01-11 4 PRIMARY DOCUMENT 0001562180-21-000284 9428
2021-01-11 4 PRIMARY DOCUMENT 0001562180-21-000283 11371
2021-01-11 4 PRIMARY DOCUMENT 0001562180-21-000282 10113
2021-01-08 8-K 8-K 8.01,9.01 0001193125-21-005232 001-37553 21517728 34 365414 1 1
2021-01-08 424B5 424B5 0001193125-21-005221 333-226691 21517691 33 1284089
2021-01-06 424B5 424B5 0001193125-21-003198 333-226691 21511075 33 1281880
2021-01-06 4 PRIMARY DOCUMENT 0001562180-21-000144 7610
2021-01-06 4 PRIMARY DOCUMENT 0001562180-21-000143 7617
2021-01-06 4 PRIMARY DOCUMENT 0001562180-21-000142 7604
2021-01-06 4 PRIMARY DOCUMENT 0001562180-21-000141 11695
2021-01-06 4 PRIMARY DOCUMENT 0001562180-21-000140 7597
2021-01-06 4 PRIMARY DOCUMENT 0001562180-21-000139 7610
2021-01-05 8-K 8-K 2.02,8.01,9.01 0001193125-21-001959 001-37553 21505686 34 220165 1 1
2020-12-30 4 PRIMARY DOCUMENT 0001562180-20-007506 12102
2020-12-28 4 PRIMARY DOCUMENT 0001562180-20-007470 6933
2020-12-28 4 PRIMARY DOCUMENT 0001562180-20-007469 9652
2020-12-22 8-K 8-K 1.01,2.03,9.01 0001193125-20-324578 001-37553 201408323 34 177468 1 1
2020-12-18 4 PRIMARY DOCUMENT 0001562180-20-007351 9656
2020-12-14 4 PRIMARY DOCUMENT 0001562180-20-007250 7395
2020-12-14 4 PRIMARY DOCUMENT 0001562180-20-007249 9652
2020-11-04 10-Q 10-Q 0001564590-20-050485 001-37553 201286886 34 12120479 1 1
2020-11-04 8-K 8-K 2.02,9.01 0001564590-20-050477 001-37553 201286842 34 587673 1 1
2020-10-27 8-K 8-K 8.01,9.01 0001193125-20-277495 001-37553 201262032 34 166911 1 1
2020-09-18 4 FORM 4 SUBMISSION 0000899243-20-025725 14515
2020-09-18 SC 13D/A SC 13D/A 0001193125-20-249155 005-89108 201184325 34 53770
2020-08-06 10-Q 10-Q 0001564590-20-037775 001-37553 201082009 34 9956870 1 1
2020-08-06 8-K 8-K 2.02,9.01 0001564590-20-037734 001-37553 201081695 34 567836 1 1
2020-07-17 4 PRIMARY DOCUMENT 0001562180-20-005162 9435
2020-07-02 8-K 8-K 5.02,9.01 0001193125-20-185954 001-37553 201007241 34 149786 1 1
2020-06-02 4 PRIMARY DOCUMENT 0001562180-20-004071 5519
2020-06-02 4 PRIMARY DOCUMENT 0001562180-20-004070 5396
2020-06-02 4 PRIMARY DOCUMENT 0001562180-20-004069 5409
2020-06-02 4 PRIMARY DOCUMENT 0001562180-20-004066 5547
2020-06-02 4 PRIMARY DOCUMENT 0001562180-20-004065 5552
2020-06-02 4 PRIMARY DOCUMENT 0001562180-20-004064 5536
2020-06-02 4 PRIMARY DOCUMENT 0001562180-20-004063 5515

Latest XBRL company facts

One latest value per concept from companyfacts (344 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 66.12M 2026-10-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
dei EntityPublicFloat Entity Public Float USD 385.01M 2025-06-30 2025 FY 10-K 2026-03-05 0001193125-26-094013
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 3.86M 2025-01-01 2025-12-31 DEF 14A 2026-04-14 0001193125-26-155058
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.92M 2025-01-01 2025-12-31 DEF 14A 2026-04-14 0001193125-26-155058
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 63.49 2025-01-01 2025-12-31 DEF 14A 2026-04-14 0001193125-26-155058
ffd NetFeeAmt NetFeeAmt USD 2,639.65 2026-06-03 SC TO-I 2026-06-03 0001193125-26-254638
ffd TtlFeeAmt TtlFeeAmt USD 2,639.65 2026-06-03 SC TO-I 2026-06-03 0001193125-26-254638
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-06-03 SC TO-I 2026-06-03 0001193125-26-254638
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-06-03 SC TO-I 2026-06-03 0001193125-26-254638
ffd TtlTxValtn TtlTxValtn USD 19.11M 2026-06-03 SC TO-I 2026-06-03 0001193125-26-254638
us-gaap AccountsAndNotesReceivableNet Accounts and Financing Receivable, after Allowance for Credit Loss USD 8.99M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 13.48M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AccountsReceivableGrossCurrent Accounts Receivable, before Allowance for Credit Loss, Current USD 42.88M 2020-06-30 2020 Q2 10-Q 2020-08-06 0001564590-20-037775
us-gaap AccountsReceivableGrossNoncurrent Accounts Receivable, before Allowance for Credit Loss, Noncurrent USD 23.01M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004920
us-gaap AccountsReceivableNet Accounts Receivable, after Allowance for Credit Loss USD 8.99M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 8.54M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AccountsReceivableNetNoncurrent Accounts Receivable, after Allowance for Credit Loss, Noncurrent USD 450,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.68M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 11.32M 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005085
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 1.73M 2015-09-30 2015 Q3 10-Q 2015-11-05 0001193125-15-367340
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 96.99M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -1.04M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.38B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 25.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 1.61M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 25.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 0 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008055
us-gaap AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current USD 4.59M 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 13.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 2.10M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap Assets Assets USD 466.04M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AssetsCurrent Assets, Current USD 320.89M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 306.27M 2018-06-30 2018 Q2 10-Q 2018-08-08 0001564590-18-020194
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 3,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 188,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 155.37M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AvailableForSaleEquitySecuritiesGrossUnrealizedGain Available-for-sale Equity Securities, Gross Unrealized Gain USD 31.78M 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap AvailableForSaleEquitySecuritiesGrossUnrealizedLoss Available-for-sale Equity Securities, Gross Unrealized Loss USD 12.20M 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022890
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD 163.91M 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 2,000 2017-12-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 468,000 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 164.38M 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss (Deprecated 2018-01-31) USD 144,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) USD 468,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value USD 61.12M 2019-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009855
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) USD 324,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value USD 61.12M 2019-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009855
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value USD 12.42M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 155.18M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap AvailableForSaleSecuritiesGrossRealizedGainLossNet Available-for-sale Securities, Gross Realized Gain (Loss) USD 7.08M 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001564590-20-037775
us-gaap AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1 Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Security 54 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap BilledContractReceivables Billed Contracts Receivable USD 2.80M 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-222804
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 330,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CapitalizedContractCostImpairmentLoss Capitalized Contract Cost, Impairment Loss USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 95.80M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 21.82M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 251.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 97.83M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 97.83M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD 25.21M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 61.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 22.03M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 100.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 66.12M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 66.12M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CommonStockValue Common Stock, Value, Issued USD 7,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -108.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ContractWithCustomerAssetNetCurrent Contract with Customer, Asset, after Allowance for Credit Loss, Current USD 372,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 22.21M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 5.99M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 16.22M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 111.39M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 16.30M 2017-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap CostMethodInvestments Cost Method Investments USD 0 2016-12-31 2016 FY 10-K 2017-03-07 0001564590-17-003576
us-gaap CostOfGoodsAndServicesSold Cost of Goods and Services Sold USD 33.57M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap CostOfGoodsSold Cost of Goods Sold (Deprecated 2018-01-31) USD 6,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap CostsAndExpenses Costs and Expenses USD 213.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 3,000 2022-01-01 2022-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 0 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD -152,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD -152,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap CustomerAdvancesCurrent Customer Advances, Current USD 127,000 2015-12-31 2016 FY 10-K 2017-03-07 0001564590-17-003576
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 1.39M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 193,000 2017-01-01 2017-06-30 2017 Q2 10-Q 2017-08-08 0001564590-17-016550
us-gaap DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-sale, Allowance for Credit Loss USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 24.14M 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss USD 81,000 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months USD 125.54M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss USD 188,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD 0 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-222804
us-gaap DebtSecuritiesAvailableForSaleUnrealizedGainLoss Debt Securities, Available-for-sale, Unrealized Gain (Loss) USD -358,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 125.54M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss USD 188,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Security 33 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap DeferredCosts Deferred Costs, Noncurrent USD 157,000 2014-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD -284,000 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008055
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD -467,000 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008055
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 33.02M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 600,000 2024-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 1.10M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 600,000 2018-09-30 2018 Q3 10-Q 2018-11-07 0001564590-18-028054
us-gaap DeferredRevenueRevenueRecognized1 Deferred Revenue, Revenue Recognized USD 7.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD -183,000 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008055
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 407.43M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 77.15M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2019-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 33.02M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 184.53M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 94.87M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent USD 495,000 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other USD 7.32M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross USD 101,000 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 374.41M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 398,000 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008055
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 1.21M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities Deferred Tax Liabilities, Unrealized Gains on Trading Securities USD 163,000 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008055
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 3.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 11.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap DueFromRelatedPartiesCurrent Due from Related Parties, Current USD 5.00M 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005085
us-gaap DueFromRelatedPartiesNoncurrent Due from Related Parties, Noncurrent USD 4.26M 2023-03-31 2023 Q1 10-Q 2023-05-03 0000950170-23-017200
us-gaap DueToOtherRelatedPartiesClassifiedCurrent Due to Other Related Parties, Current USD 3.76M 2014-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap DueToRelatedPartiesCurrent Due to Related Parties, Current USD 1.42M 2014-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.9 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -1.79 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-04 0001564590-22-017878
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.9 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.208 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.007 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.028 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.039 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 16.04M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 45.80M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 26.00M 2017-06-30 2017 Q2 10-Q 2017-08-08 0001564590-17-016550
us-gaap EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage pure 0.2 2021-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008055
us-gaap FairValueAssetsLevel1ToLevel2TransfersAmount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount USD 0 2020-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009855
us-gaap FairValueAssetsLevel2ToLevel1TransfersAmount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount USD 0 2020-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009855
us-gaap FinanceLeaseLiabilityNoncurrent Finance Lease, Liability, Noncurrent USD 5.85M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap FinancingReceivableAllowanceForCreditLosses Financing Receivable, Allowance for Credit Loss USD 4.94M 2024-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-122330
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD -100,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap ForeignCurrencyTransactionGainLossUnrealized Foreign Currency Transaction Gain (Loss), Unrealized USD 2,000 2016-01-01 2016-09-30 2016 Q3 10-Q 2016-11-09 0001564590-16-028642
us-gaap GainLossOnInvestments Gain (Loss) on Investments USD 2.21M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061144
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 63.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ImpairmentOfInvestments Other than Temporary Impairment Losses, Investments USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004920
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 2.10M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -193.79M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -193.88M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD -83,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxesPaid Income Taxes Paid USD 904,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 285,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 280,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 40.42M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -40.71M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 1.14M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 5.38M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -16,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount USD 27,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 7.49M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap IncreaseDecreaseInAccountsPayableRelatedParties Increase (Decrease) in Accounts Payable, Related Parties USD -34,000 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap IncreaseDecreaseInAccountsPayableTrade Increase (Decrease) in Accounts Payable, Trade USD -6.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -19.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 758,000 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-05 0001193125-15-367340
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD -9.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -600,000 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040403
us-gaap IncreaseDecreaseInCustomerAdvances Increase (Decrease) in Customer Advances USD -127,000 2016-01-01 2016-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -7.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap IncreaseDecreaseInDueFromRelatedPartiesCurrent Increase (Decrease) in Due from Related Parties, Current USD -750,000 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap IncreaseDecreaseInDueToOtherRelatedPartiesCurrent Increase (Decrease) in Due to Other Related Parties, Current USD -3.76M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap IncreaseDecreaseInOtherCurrentAssets Increase (Decrease) in Other Current Assets USD 35.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 687,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD 1.35M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-07 0001564590-19-030100
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD -163,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap IncreaseDecreaseInPrepaidExpense Increase (Decrease) in Prepaid Expense USD 1.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap IncreaseDecreaseInRestrictedCash Increase (Decrease) in Restricted Cash USD 225,000 2016-01-01 2016-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap IncreaseDecreaseInUnbilledReceivables Increase (Decrease) in Unbilled Receivables USD -327,000 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap InterestExpense Interest Expense USD 2.42M 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-01 0000950170-24-089320
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 23.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 7,000 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 5.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap InvestmentIncomeNet Investment Income, Net USD 5.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap LeaseCost Lease, Cost USD 13.87M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 97.24M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 50.85M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 12.24M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 8.13M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 8.05M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 7.94M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 10.02M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 594,000 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040403
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 23.74M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap Liabilities Liabilities USD 318.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 466.04M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap LiabilitiesAssumed1 Liabilities Assumed USD 265,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008055
us-gaap LiabilitiesCurrent Liabilities, Current USD 67.68M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap LicenseAndMaintenanceRevenue License and Maintenance Revenue (Deprecated 2018-01-31) USD 920,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap LicenseAndServicesRevenue License and Services Revenue (Deprecated 2018-01-31) USD 1.20M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap LicenseCosts License Costs (Deprecated 2018-01-31) USD 2.41M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap LicensesRevenue Licenses Revenue (Deprecated 2018-01-31) USD 132.39M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap LitigationReserve Estimated Litigation Liability USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap LitigationSettlementAmountAwardedFromOtherParty Litigation Settlement, Amount Awarded from Other Party USD 7.50M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap LitigationSettlementGain LitigationSettlementGain USD 38.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap LitigationSettlementLoss LitigationSettlementLoss USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap LossContingencyAccrualProvision Loss Contingency Accrual, Provision USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap LossContingencyDamagesPaidValue Loss Contingency, Damages Paid, Value USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 155.18M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 10.79M 2025-12-31 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap MarketableSecuritiesRealizedGainLoss Marketable Securities, Realized Gain (Loss) USD 4.80M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005085
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 110.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 4.17M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 50.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -37.09M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -99.81M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD 58.13M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -108.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -263.49M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021161
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -263.49M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021161
us-gaap NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification (Deprecated 2020-01-31) USD 4.80M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004920
us-gaap NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1 Noncash or Part Noncash Divestiture, Amount of Consideration Received USD 1.12M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008055
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -18.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap NotesPayableRelatedPartiesClassifiedCurrent Notes Payable, Related Parties, Current USD 2.40M 2014-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021161
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -89.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OperatingLeaseCost Operating Lease, Cost USD 11.26M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 1.40M 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-08 0000950170-24-055691
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 73.50M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 6.49M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 60.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OperatingLeasePayments Operating Lease, Payments USD 13.07M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 42.25M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 96.54M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 2.80M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004920
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 5.63M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 4.91M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 3.72M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 3.05M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 76.42M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 2.80M 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 2.80M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009855
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.057 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.89M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OtherAssetsCurrent Other Assets, Current USD 48.15M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 5.30M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax USD 3.69M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -358,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -358,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax USD 479,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-08 0001564590-17-022765
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax USD -342,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -358,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax USD 500,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006826
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 475,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OtherNoncashExpense Other Noncash Expense USD 3,000 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD 8,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 483,000 2016-01-01 2016-03-31 2016 Q1 10-Q 2016-05-05 0001564590-16-017818
us-gaap OtherOperatingIncome Other Operating Income USD 26,000 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap OtherOperatingIncomeExpenseNet Other Operating Income (Expense), Net USD -117,000 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001564590-20-037775
us-gaap OtherPrepaidExpenseCurrent Other Prepaid Expense, Current USD 1.36M 2026-06-30 2026 Q2 10-Q 2026-08-06 0001193125-26-336725
us-gaap OtherReceivableAfterAllowanceForCreditLossNoncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent USD 4.15M 2022-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021161
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 4.59M 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap OtherSalesRevenueNet Other Revenue, Net (Deprecated 2018-01-31) USD 213,000 2016-01-01 2016-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale USD 0 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061144
us-gaap OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings USD 0 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040403
us-gaap OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities Other than Temporary Impairment Losses, Investments, Available-for-sale Securities USD 0 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap PaymentsForFees Payments for Other Fees USD 300,000 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap PaymentsForProceedsFromTenantAllowance Payments for (Proceeds from) Tenant Allowance USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap PaymentsForRestructuring Payments for Restructuring USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 249,000 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-01 0000950170-24-089320
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 138.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 2.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap PreferredStockDividendsAndOtherAdjustments Preferred Stock Dividends and Other Adjustments USD 1.75M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 13.01M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 107.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 19.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 1.97M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 4.87M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-13 0000950170-25-038770
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised USD 1.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProceedsFromLegalSettlements Proceeds from Legal Settlements USD 39.00M 2026-10-01 2026-10-31 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProceedsFromRelatedPartyDebt Proceeds from Related Party Debt USD 2.40M 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-07 0001564590-17-003576
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 62,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 179.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 11.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 844,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -108.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap PropertyPlantAndEquipmentAdditions Property, Plant and Equipment, Additions USD 2.30M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005085
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 192.33M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 95.35M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ProvisionForLoanLeaseAndOtherLosses Provision for Loan, Lease, and Other Losses USD -5.00M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap ProvisionForOtherCreditLosses Provision for Other Credit Losses USD -5.00M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap RealizedInvestmentGainsLosses Realized Investment Gains (Losses) USD 16,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ReceivablesNetCurrent Receivables, Net, Current USD 8.54M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap RedeemableNoncontrollingInterestEquityPreferredCarryingAmount Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount USD 12.59M 2014-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap RelatedPartyCosts Related Party Costs USD 861,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001564590-17-003576
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 174.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 1.80M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 225,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap RestructuringCharges Restructuring Charges USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap RestructuringReserve Restructuring Reserve USD 0 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap RestructuringReservePeriodIncreaseDecrease Restructuring Reserve, Period Increase (Decrease) USD -400,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap RestructuringReserveTranslationAndOtherAdjustment Restructuring Reserve, Translation and Other Adjustment USD -436,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.23B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 123.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax USD 123.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap RevenueFromGrants Revenue from Grants (Deprecated 2018-01-31) USD 8,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap RevenueFromRelatedParties Revenue from Related Parties USD 2.00M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap Revenues Revenues USD 132.39M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011844
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 93,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap SegmentReportingOtherItemAmount SegmentReportingOtherItemAmount USD -19.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 25.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.64 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.043 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 148.04M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 111.39M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-06 0001564590-18-004532
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 1.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 18.88M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-06 0001193125-26-336725
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 816,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap SubleaseIncome Sublease Income USD 451,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2014-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 4.30M 2014-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013941
us-gaap TradeReceivablesHeldForSaleAmount Accounts Receivable, Held-for-sale USD 609,000 2015-09-30 2015 Q3 10-Q 2015-11-05 0001193125-15-367340
us-gaap UnbilledContractsReceivable Unbilled Contracts Receivable USD 16.50M 2020-06-30 2020 Q2 10-Q 2020-08-06 0001564590-20-037775
us-gaap UnbilledReceivablesCurrent Unbilled Receivables, Current USD 20.11M 2024-12-31 2025 Q2 10-Q 2025-08-07 0001193125-25-174953
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 100,000 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 36.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap VariableLeaseCost Variable Lease, Cost USD 3.06M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094013
us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number Diluted Shares Outstanding Adjustment shares 52.63M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-06 0001193125-26-336725
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 56.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 42,944 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-04 0001564590-22-017878
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 56.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448581

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →